Phage Therapy

A topical collection in Viruses (ISSN 1999-4915). This collection belongs to the section "Bacterial Viruses".

Viewed by 2729

Editors


E-Mail Website
Collection Editor
Eliava Institute of Bacteriophage, Microbiology and Virology, Gotua Street 3, Tbilisi 0160, Georgia
Interests: bacteriophage research; phage therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Collection Editor
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Interests: bacteriophage; phage therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Collection Editor
Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland
Interests: phage-host interactions; Yersinia virulence; bacteriophage therapy
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

This Topical Collection on Phage Therapy aims to provide an opportunity for scientists, physicians, veterinarians, and plant pathologists to publish research on topics related to bacteriophages and their applications, a field currently known as “phage therapy”. The collection will accept original articles, reviews, case studies, short communications, and method descriptions. It will also accommodate expert opinions, discussions, or decisions on bacteriophage manufacturing processes and regulations, as well as meeting reports and personal viewpoints or hypotheses.

The goal of this open access Topical Collection is to promote communication among stakeholders from academic, healthcare, and industry sectors, including regulators and policy makers. It will also generate a citable information source on the effective use of bacteriophages as a much-needed additional antibacterial, to gain broader acceptance for phage therapy throughout the world.

Dr. Nina Chanishvili
Dr. Jean-Paul Pirnay
Dr. Mikael Skurnik
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phage therapy
  • bacteriophage
  • antibacterial

Published Papers (2 papers)

2025

11 pages, 375 KiB  
Article
High-Performance Genome Annotation for a Safer and Faster-Developing Phage Therapy
by Antoine Culot, Guillaume Abriat and Kieran P. Furlong
Viruses 2025, 17(3), 314; https://doi.org/10.3390/v17030314 - 25 Feb 2025
Viewed by 861
Abstract
Phage therapy, which uses phages to decrease bacterial load in an ecosystem, introduces a multitude of gene copies (bacterial and phage) into said ecosystem. While it is widely accepted that phages have a significant impact on ecology, the mechanisms underlying their impact are [...] Read more.
Phage therapy, which uses phages to decrease bacterial load in an ecosystem, introduces a multitude of gene copies (bacterial and phage) into said ecosystem. While it is widely accepted that phages have a significant impact on ecology, the mechanisms underlying their impact are not well understood. It is therefore paramount to understand what is released in the said ecosystem, to avoid alterations with difficult-to-predict—but potentially huge—consequences. An in-depth annotation of therapeutic phage genomes is therefore essential. Currently, the average published phage genome has only 20–30% functionally annotated genes, which represents a hurdle to overcome to deliver safe phage therapy, for both patients and the environment. This study aims to compare the effectiveness of manual versus automated phage genome annotation methods. Twenty-seven phage genomes were annotated using SEA-PHAGE and Rime Bioinformatics protocols. The structural (gene calling) and functional annotation results were compared. The results suggest that during the structural annotation step, the SEA-PHAGE method was able to identify an average of 1.5 more genes per phage (typically a frameshift gene) and 5.3 gene start sites per phage. Despite this difference, the impact on functional annotation appeared to be limited: on average, 1.2 genes per phage had erroneous functions, caused by the structural annotation. Rime Bioinformatics’ tool (rTOOLS, v2) performed better at assigning functions, especially where the SEA-PHAGE methods assigned hypothetical proteins: 7.0 genes per phage had a better functional annotation on average, compared to SEA PHAGE’s 1.7. The method comparison detailed in this article indicate that (1) manual structural annotation is marginally superior to rTOOLS automated structural annotation; (2) rTOOLS automated functional annotation is superior to manual functional annotation. Previously, the only way to obtain a high-quality annotation was by using manual protocols, such as SEA-PHAGES. In the relatively new field of phage therapy, which requires support to advance, manual work can be problematic due to its high cost. Rime Bioinformatics’ rTOOLS software allows for time and money to be saved by providing high-quality genome annotations that are comparable to manual results, enabling a safer and faster-developing phage therapy. Full article
Show Figures

Figure 1

16 pages, 2236 KiB  
Article
Klebsiella pneumoniae Phage M198 and Its Therapeutic Potential
by Lika Leshkasheli, Ia Kusradze, Darejan Bolkvadze, Lia Askilashvili, Maria Chichashvili, Giorgi Tsertsvadze and Elisabed Zaldastanishvili
Viruses 2025, 17(1), 115; https://doi.org/10.3390/v17010115 - 15 Jan 2025
Viewed by 946
Abstract
The rapid worldwide spread of antibiotic resistance is quickly becoming an increasingly concerning problem for human healthcare. Non-antibiotic antibacterial agents are in high demand for many Gram-negative bacterial pathogens, including Klebsiella pneumoniae. Klebsiella-targeting phages are among the most promising alternative therapy [...] Read more.
The rapid worldwide spread of antibiotic resistance is quickly becoming an increasingly concerning problem for human healthcare. Non-antibiotic antibacterial agents are in high demand for many Gram-negative bacterial pathogens, including Klebsiella pneumoniae. Klebsiella-targeting phages are among the most promising alternative therapy options. They have already been successfully applied in a number of cases, and it is expected that the need for anti-Klebsiella phages will only increase in the future. This prospect highlights the need for well-characterized therapeutic phages. In this work, we describe a K. pneumoniae phage, which also infects strains of Klebsiella oxytoca. Here, we characterize phage M198 in terms of its biological and genetic properties. Since in some phage therapy cases, phages are administered in combination with antibiotics, here, we also screen for possible synergistic effects of combining phage M198 with six different antibiotics. We found that phage M198 has good lytic activity against clinical isolates; it does not have any indications of a temperate lifestyle, and it has synergistic potential when combined with some therapeutically relevant antibiotics. Full article
Show Figures

Figure 1

Back to TopTop